Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period
Phase of Trial: Phase IV
Latest Information Update: 11 May 2016
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin; Simeprevir; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 03 May 2016 Status changed from active, no longer recruiting to completed.
- 17 Apr 2016 Results of the sustained virologic response at 12 weeks post treatment (n=226) presented at The International Liver Congress 2016.
- 08 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016, as reported by ClinicalTrials.gov record.